PTC Therapeutics (PTCT) Misses Q4 EPS by 39c

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($2.03), $0.39 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $165.2 million versus the consensus estimate of $150.83 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Ross Stores raises 2026 outlook after strong second-quarter results
• Citi cuts Weibo stock rating to Neutral, lowers price target